Evidence map›Paper›PMID 29131160›Full record

ArticleNature medicine2017

Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

Laura Broutier, Gianmarco Mastrogiovanni, Monique Ma Verstegen, Hayley E Francies, Lena Morrill Gavarró, Charles R Bradshaw, George E Allen, Robert Arnes-Benito, Olga Sidorova, Marcia P Gaspersz and 12 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 829 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
829citing papers in PubMed, 3 pooled it
48.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05196334 recruitingnot on this mapstarted 2021, after this paper: background citation

Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response

TypeobservationalSponsorHerlev HospitalRan2021 to 2025Enrolled88ConditionsPancreatic CancerArmsNo intervention
NCT06355700 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Hepatocellular Carcinoma Organoids to Explore Tumor Microenvironment and Test Treatment Efficacy - Hepatocellular Carcinoma Liver Organoids (HELIO)

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2023 to 2025Enrolled10ConditionsHepatocellular CarcinomaArmsLiver biopsy
3 · Its place in the literature

Who cites it

829 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,426 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026
    Review

769 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Laura BroutierThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5163-5573
Gianmarco MastrogiovanniThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
Monique Ma VerstegenDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Hayley E FranciesWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Lena Morrill GavarróWellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK.
Charles R BradshawThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
George E AllenThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
Robert Arnes-BenitoThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
Olga SidorovaThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
Marcia P GasperszDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Nikitas GeorgakopoulosDepartment of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Bon-Kyoung KooWellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK.
Sabine DietmannWellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK.
Susan E DaviesDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Raaj K PraseedomDepartment of Hepato Pancreato Biliary Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Ruby LieshoutDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Jan N M IJzermansDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Stephen J WigmoreDepartment of Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.
Kourosh Saeb-ParsyDepartment of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Mathew J GarnettWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Luc Jw van der LaanDepartment of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
Meritxell HuchThe Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-1545-5265
University of Cambridge · GBErasmus MC · NLWellcome/MRC Cambridge Stem Cell Institute · GBCambridge University Hospitals NHS Foundation Trust · GBWellcome Sanger Institute · GBEdinburgh Royal Infirmary · GB

Funding

Cancer Research UK 22536National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/R001162/1Wellcome Trust 104151
6 · The paper itself

Abstract

Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a novel, near-physiological organoid culture system, wherein primary human healthy liver cells form long-term expanding organoids that retain liver tissue function and genetic stability. Here we extend this culture system to the propagation of primary liver cancer (PLC) organoids from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC (CHC) tumors. PLC-derived organoid cultures preserve the histological architecture, gene expression and genomic landscape of the original tumor, allowing for discrimination between different tumor tissues and subtypes, even after long-term expansion in culture in the same medium conditions. Xenograft studies demonstrate that the tumorogenic potential, histological features and metastatic properties of PLC-derived organoids are preserved in vivo. PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer. We thus demonstrate the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease.

Indexed as

AnimalsAntineoplastic AgentsBile Duct NeoplasmsCarcinoma, HepatocellularCell ProliferationCholangiocarcinomaDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiceMice, Inbred NODMice, SCIDOrganoidsPrecision MedicineAntineoplastic Agents

Identifiers

PMID29131160
PMCPMC5722201
OpenAlexW2771057425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.